6951-17-3

Usage

Uses

Used in Pharmaceutical Applications:
Curcumin III is used as a therapeutic agent for its potential role in the treatment of various diseases, including cancer, diabetes, and neurodegenerative disorders. Its anti-inflammatory and antioxidant properties contribute to its potential health benefits.
Used in Anticancer Applications:
In the field of oncology, Curcumin III is used as an anticancer agent. It may help in the treatment of various types of cancer due to its ability to modulate multiple signaling pathways involved in cancer progression.
Used in Nutraceutical Applications:
Curcumin III is also used in the nutraceutical industry for its potential health-promoting and disease-preventing properties. Its presence in dietary supplements may contribute to overall health and well-being.
Used in Research and Development:
In the research and development sector, Curcumin III is utilized for its potential applications in the development of new drugs and therapies, particularly in the areas of cancer treatment and neurodegenerative disease management.
Used in Cosmetic Applications:
Due to its antioxidant properties, Curcumin III may also be used in the cosmetic industry for products aimed at promoting skin health and reducing signs of aging.
Used in Food Industry:
In the food industry, Curcumin III could be used as a natural additive for its color and potential health benefits, enhancing the nutritional value of various food products.

Upstream product

• 94299-22-6 3,4-Dimethoxy-2-nicotinoyloxi-acetophenon 
• 5396-18-9 2'-hydroxy-3',4'-dimethoxyacetophenone 

Downstream Products

• 6622-57-7 7,8-Dimethoxy-2-pyridyl-(3)-chromon 

Relevant academic research and scientific papers

Novel synthesised flavone derivatives provide significant insight into the structural features required for enhanced anti-proliferative activity

With many cancers showing resistance to current chemotherapies, the search for novel anti-cancer agents is attracting considerable attention. Natural flavonoids have been identified as useful leads in such programmes. However, since an in-depth understanding of the structural requirements for optimum activity is generally lacking, further research is required before the full potential of flavonoids as anti-proliferative agents can be realised. Herein a broad library of 76 methoxy and hydroxy flavones, and their 4-thio analogues, was constructed and their structure-activity relationships for anti-proliferative activity against the breast cancer cell lines MCF-7 (ER +ve), MCF-7/DX (ER +ve, anthracycline resistant) and MDA-MB-231 (ER -ve) were probed. Within this library, 42 compounds were novel, and all compounds were afforded in good yields and >95% purity. The most promising lead compounds, specifically the novel hydroxy 4-thioflavones 15f and 16f, were further evaluated for their anti-proliferative activities against a broader range of cancer cell lines by the National Cancer Institute (NCI), USA and displayed significant growth inhibition profiles (e.g. compound-15f: MCF-7 (GI50 = 0.18 μM), T-47D (GI50 = 0.03 μM) and MDA-MB-468 (GI50 = 0.47 μM) and compound-16f: MCF-7 (GI50 = 1.46 μM), T-47D (GI50 = 1.27 μM) and MDA-MB-231 (GI50 = 1.81 μM)). Overall, 15f and 16f exhibited 7-46 fold greater anti-proliferative potency than the natural flavone chrysin (2d). A systematic structure-activity relationship study against the breast cancer cell lines highlighted that free hydroxyl groups and the B-ring phenyl groups were essential for enhanced anti-proliferative activities. Substitution of the 4-CO functionality with a 4-CS functionality, and incorporation of electron withdrawing groups at C-4′ of the B-ring phenyl, also enhanced activity. Molecular docking and mechanistic studies suggest that the anti-proliferative effects of flavones 15f and 16f are mediated via ER-independent cleavage of PARP and downregulation of GSK-3β for MCF-7 and MCF-7/DX cell lines. For the MDA-MB-231 cell line, restoration of the wild-type p53 DNA binding activity of mutant p53 tumour suppressor gene was indicated.